| Product Code: ETC069988 | Publication Date: Jun 2021 | Updated Date: Aug 2025 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market - Industry Life Cycle |
3.4 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market - Porter's Five Forces |
3.5 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume Share, By Vector, 2021 & 2031F |
3.6 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing demand for personalized medicines and advanced therapies |
4.2.2 Increasing research and development activities in cell and gene therapy |
4.2.3 Favorable regulatory environment supporting cell and gene therapy manufacturing |
4.3 Market Restraints |
4.3.1 High cost associated with cell and gene therapy manufacturing |
4.3.2 Limited skilled workforce in specialized manufacturing processes |
4.3.3 Challenges in scaling up production to meet market demand |
5 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Trends |
6 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market, By Types |
6.1 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market, By Vector |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Vector, 2018 - 2027F |
6.1.3 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Viral Vector, 2018 - 2027F |
6.1.4 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Non-viral Vector, 2018 - 2027F |
6.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Cancer, 2018 - 2027F |
6.2.3 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Neurological Diseases, 2018 - 2027F |
6.2.4 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Hepatological Diseases, 2018 - 2027F |
6.2.5 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenues & Volume, By Others, 2018 - 2027F |
7 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Export to Major Countries |
7.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Imports from Major Countries |
8 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Key Performance Indicators |
8.1 Percentage increase in the number of clinical trials utilizing cell and gene therapies in the UK |
8.2 Adoption rate of automated manufacturing technologies in cell and gene therapy production facilities |
8.3 Number of partnerships and collaborations between UK contract manufacturers and biopharmaceutical companies in the cell and gene therapy space. |
9 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market - Opportunity Assessment |
9.1 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Opportunity Assessment, By Vector, 2021 & 2031F |
9.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market - Competitive Landscape |
10.1 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Revenue Share, By Companies, 2021 |
10.2 United Kingdom (UK) Contract Cell and Gene Therapy Manufacturing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here